PLUR
Pluri Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-2.07
P/S
19.88
EV/EBITDA
-2.40
DCF Value
$-19.62
FCF Yield
-82.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
21.3%
Operating Margin
-1857.9%
Net Margin
-1952.1%
ROE
280.4%
ROA
-85.4%
ROIC
-92.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $198.0K | $-6.5M | $-0.71 |
| Q1 2026 | $316.0K | $-5.8M | $-0.65 |
| Q4 2025 | $398.0K | $-7.6M | $-0.96 |
| FY 2025 | $1.3M | $-22.6M | $-3.56 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
0.72
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.